Dow Jones 12110.41 -49.27 11:23 pm PDT, March 17, 2007 NASDAQ 2372.66 -6.04 For info, visit access.smallcapnetwork.com S & P 500 1386.95 -5.33 Change your subscription status here Russell 2000 778.77 -4.84 VOLUME 07: ISSUE 30 Could CEL-SCI Be A Lucky Charm? Happy Saint Patrick's Day! If you're wishing for the luck o' the Irish to work its way into your stock trading, we may have a lucky charm for you today. Gratuitous Saint Patrick's Day clichés aside.....  As we mentioned in the blog a couple of days ago, CEL-SCI Corporation (AMEX:CVM) has a new investor webcast out. Having had a chance to review it for ourselves, we have to say our enthusiasm has been fully renewed here. Whether you're currently a shareholder or just thinking about it, we recommend you take a look as well. Details on how to find the webcast archive are below.  For the most part, we knew what the presentation was going to say. We've been following the company's development of its key head and neck cancer treatment - called Multikine - for a few years. So in a sense, we've really gotten to know the company.  But, CEO Geert Kersten had some additional insights in the webcast we feel merit repeating, though we'd be the first to admit you're still far better off going over the presentation for yourself. We'll tease you with a few highlights of the webcast today, with a particular focus on the two new facets we haven't looked at with much detail until now.    CEL-SCI's Bread & Butter Just to get everybody up to speed, Multikine is an immunotherapy designed to enhance other forms of head and neck cancer treatments like surgery, radiation, and chemo. All well and good, but the real question we have as investors is....does Multikine have enough of an impact to be viable?  Based on what we've seen from the company so far, we'd have to say it really looks that way. Check it out....  In phase II testing, their research shows a 33% increase in the overall survival rate of head and neck cancer patients. Folks, we feel that's a pretty nice perk to have considering the circumstances - the kind of advantage most patients would love to have. It's also the kind of advantage most insurance companies would like to have, since in the latter stages of cancer, as well as recurrent cancer, higher costs start to kick in. If Multikine can help beat cancer early and completely, we'd say the value is obvious.  Well, you may recall Multikine was recently given the green light to move into phase III testing. Phase III is the final stage of the process needed to get any final approval from the FDA (or the Canadian equivalent, since Multikine is also approved for phase III there).  As promised though, there were two other key ideas brought up in the webcast we really haven't put on the table yet....    "Two For The Show" First up - can Multikine get through this third and last stage of testing? Never start counting your gold coins until you get to the end of the rainbow, but it sure looks encouraging. The exact same treatment formula and process used in phase II is being used in phase III, so we wouldn't expect the results to be much different - if at all.  And just as a reminder, those phase II results were a 33% increase in the overall survival rate.  So far so good, right? Here's the part we didn't know.....historically, about 2/3 of phase III studies end up getting the required regulatory approval. For the treatments that end up not being approved, one of the most common reasons for rejection is safety concerns. The thing is, CEL-SCI has yet to see any major adverse side effects with Multikine, leading them to believe there won't be any major safety concerns during phase III trials.  The second idea - CEL-SCI's valuation. In a nutshell, it doesn't make sense to us, especially now that the company is in the latter stages of developing what looks like a very effective cancer treatment that could save tens of thousands (if not millions) of dollars on a per-patient basis. The valuation just seems way too low.  The company already did the number crunching.....with 500,000 new head and neck cancer cases being diagnosed every year, the potential market is enormous. If CEL-SCI's treatment is only used by 10% of those patients, at $25,000 per treatment, you're looking at possibly $1.25 billion in annual revenue.  The other side of the equation - CEL-SCI's current market cap is only $60 million...$60 million! And if Multikine passes these last tests, they're looking at what could be more than a billion bucks in annual sales! Say what?  But here's what we think is the jaw-dropper....the current institutional ownership of CVM stock? A mere 1.2% of outstanding shares.  Do we even need to say it? (We will, of course.) If the institutions start looking at the upside versus the downside, what do you think they'll do? We feel the odds are easily in CEL-SCI shares' favor, to say the least. A $60 million market cap currently, but a potential billion dollar opportunity? We just get the feeling that Multikine's progress is going to start turning heads, and possibly stirring up some serious demand from the big players. If that happens, there's a shot at some colossal gains as any buying frenzy grows.  Yes, like we said above, there's always risk. But, there may not be quite as much as you think there would be with this kind of biotech venture... Multikine's phase III seems to have so many things already working in its favor.  Oh, and did we mention Multikine may have a practical application in treatments of other cancers? The testing so far has strictly been in the head and neck cancer arena, but the worldwide annual market for all cancers is expected to be, by some estimates, around $80 billion by 2010. Interested now?    There's More in Store Our take today only scratches the surface of what you'll find in the webcast. We really do encourage you to invest a few minutes of your time so you can get up close and personal with this company, what they're doing, and what it may mean to investors. We were blown away (again) when we saw the webcast, and we suspect you'll be impressed too.  Could CEL-SCI end up being a lucky four-leaf clover in your portfolio? We'll say this much....unless you've got a leprechaun delivering a pot of gold to your house later today, we'd suggest an alternative way to try and build your fortune is with opportunities like CEL-SCI Corporation.  But you don't even have to adopt our opinion - you can decide for yourself after you review the latest presentation by clicking here. The link is labeled on that page. Window's Media Player is required. In the meantime, have a happy and safe Saint Patrick's Day!     We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Email the Editor If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 Subscribe Information is power and timely information is profitable. Become informed and profit from Small Cap Network Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the Small Cap Network Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the Small Cap Network Member List. Receiving the Small Cap Network Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the Small Cap Network recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the Small Cap Network Newsletter, simply follow the instructions located at the bottom of every Small Cap Network Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCN") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCN is owned and operated by TGR Group, LLC ("TGR"). All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCN. To the degrees enumerated herein, SCN should not be regarded as an independent publication.  Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://access.smallcapnetwork.com/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts.  TGR Group LLC has been paid a fee of $25,000 and 150,000 shares of newly issued restricted stock by Cel-Sci for coverage of the Company. Additionally, back in November of 2002, TGR Group LLC was paid a fee of $25,000 and 250,000 shares of newly issued restricted stock of Cel-Sci for coverage of the company until November of 2003. The aforementioned 250,000 restricted shares became free trading under SEC rule 144 and were sold in the open market prior to the company entering into a new contract agreement with TGR Group in February of 2006. From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.  TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed.  All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCN is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.  The profiles, critiques, and other editorial content of SCN may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.  THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR.  We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.